NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer

[1]  A. Mes-Masson,et al.  Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models , 2021, Scientific Reports.

[2]  A. Mes-Masson,et al.  Ran GTPase: A Key Player in Tumor Progression and Metastasis , 2020, Frontiers in Cell and Developmental Biology.

[3]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[4]  M. Gordon,et al.  Cellular Stress Associated with Aneuploidy. , 2018, Developmental cell.

[5]  S. Mocellin,et al.  Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies , 2018, BMC Medicine.

[6]  A. Saghatelian,et al.  Pharmacological activation of REV-ERBs is lethal in cancer and oncogene induced senescence , 2018, Nature.

[7]  Mi-Ock Lee,et al.  NR1D1 enhances oxidative DNA damage by inhibiting PARP1 activity , 2017, Molecular and Cellular Endocrinology.

[8]  H. Na,et al.  NR1D1 Recruitment to Sites of DNA Damage Inhibits Repair and Is Associated with Chemosensitivity of Breast Cancer. , 2017, Cancer research.

[9]  D. Lambrechts,et al.  Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals. , 2017, Developmental cell.

[10]  A. Mes-Masson,et al.  Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines , 2016, Oncotarget.

[11]  Yu Pan,et al.  RCC1-dependent activation of Ran accelerates cell cycle and DNA repair, inhibiting DNA damage–induced cell senescence , 2016, Molecular biology of the cell.

[12]  C. Dang,et al.  MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. , 2015, Cell Metabolism.

[13]  A. Mes-Masson,et al.  Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease , 2015, Genes & cancer.

[14]  D. Kojetin,et al.  Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells. , 2015, Biochemical pharmacology.

[15]  Liang Zhao,et al.  FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.

[16]  A. Mes-Masson,et al.  RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer , 2014, PloS one.

[17]  D. Fan,et al.  Ran GTPase protein promotes human pancreatic cancer proliferation by deregulating the expression of Survivin and cell cycle proteins. , 2013, Biochemical and biophysical research communications.

[18]  Ali Bashashati,et al.  Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.

[19]  J. Eeckhoute,et al.  Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy , 2013, Nature Medicine.

[20]  P. Kalab,et al.  Chromosomal gain promotes formation of a steep RanGTP gradient that drives mitosis in aneuploid cells , 2013, The Journal of cell biology.

[21]  Marie-christine Caron,et al.  PARP activation regulates the RNA-binding protein NONO in the DNA damage response to DNA double-strand breaks , 2012, Nucleic acids research.

[22]  Anne-Marie Mes-Masson,et al.  Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer , 2012, BMC Cancer.

[23]  Logan J Everett,et al.  Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function. , 2012, Genes & development.

[24]  J. Takahashi,et al.  Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists , 2012, Nature.

[25]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  A. Mes-Masson,et al.  An essential role for Ran GTPase in epithelial ovarian cancer cell survival , 2010, Molecular Cancer.

[28]  D. Altieri,et al.  A Survivin-Ran Complex Regulates Spindle Formation in Tumor Cells , 2008, Molecular and Cellular Biology.

[29]  A. Mes-Masson,et al.  Characterization of three new serous epithelial ovarian cancer cell lines , 2008, BMC Cancer.

[30]  C. Le Page,et al.  Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer , 2006, International journal of cancer.

[31]  Anne-Marie Mes-Masson,et al.  Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling , 2005, Oncogene.

[32]  C. Lengauer,et al.  Aneuploidy and cancer , 2004, Nature.

[33]  Ueli Schibler,et al.  The Orphan Nuclear Receptor REV-ERBα Controls Circadian Transcription within the Positive Limb of the Mammalian Circadian Oscillator , 2002, Cell.

[34]  Alexey Khodjakov,et al.  Merotelic Kinetochore Orientation Is a Major Mechanism of Aneuploidy in Mitotic Mammalian Tissue Cells , 2001, The Journal of cell biology.

[35]  Alfred Wittinghofer,et al.  Structural Basis for Guanine Nucleotide Exchange on Ran by the Regulator of Chromosome Condensation (RCC1) , 2001, Cell.

[36]  A. Mes-Masson,et al.  Characterization of four novel epithelial ovarian cancer cell lines , 2000, In Vitro Cellular & Developmental Biology - Animal.

[37]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[38]  S. Barik,et al.  MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. , 2011, Molecular and cellular pharmacology.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.